NCT05558358进行中（未招募）1 期
Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Incidence of study-emergent adverse events
研究概览
简要总结
We will evaluate the effects of deep brain stimulation (DBS) of bilateral nucleus accumbens (NAc) added to background treatment for treatment refractory Methamphetamine Use Disorder (MUD). This is a small randomized cross-over study to demonstrate feasibility and safety, test treatment outcomes (use, craving), and identify novel biological targets (NAc local field potentials (LFP) and functional MRI).
详细描述
In a randomized cross-over design of DBS of the nucleus accumbens (NAc) for treatment refractory methamphetamine use disorder (MUD, n=5), we will test safety, feasibility, effect on clinical outcomes (craving and use), and seek to identify biological targets (using cue craving during recording of local field potentials and MRI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
盲法说明
Participants and all study personnel are blinded to subject assignment except the physician completing DBS programming.
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (men and non-pregnant or nursing women) between 22-65 years of age will be eligible for enrollment, if meeting the following criteria:
- •Current diagnosis of DSM-5 MUD (with past year specifier of severe and at least a 5-year history);
- •Failed at least 2 prior treatment episodes (defined as outpatient or inpatient, utilizing a previously validated psychosocial treatment for addiction such as cognitive behavioral therapy, contingency management, motivational interviewing (Stuart et al., 2019) and not counting episodes with only detoxification) for MUD, with at least 1 episode having been residential;
- •Provides a urine drug screen positive for mAMP;
- •Endorses at least 10 days of mAMP use in the past month;
- •Able to complete 1 week of inpatient detoxification prior to surgery and 4 weeks of inpatient treatment following surgery;
- •No change in current psychiatric medication regimen, or medication free, for at least 4 weeks prior to entry;
- •Able to provide informed consent;
- •Able to comply with all testing and follow-up requirements as defined by study protocol (including providing a home address and two local collateral contacts);
- •Medically able to undergo DBS procedure as assessed by Study Neurosurgeon;
- •Has platelet count, PT and PTT within normal laboratory limits;
- •Adequate English proficiency for study consent, and completion of the study instruments;
- •Reside in the state of Colorado.
排除标准
- •Lifetime non-substance-induced psychotic disorders, schizophrenia, or schizoaffective disorder defined by DSM-5;
- •Current diagnosis of DSM-5 drug use disorder other than stimulant, alcohol, cannabis or nicotine use disorder;
- •Non-substance-induced manic episode within the past 3 years or major depressive episode in the past year;
- •Current clinically significant neurological disorder or medical illness;
- •Presence of a clinically significant abnormality on preoperative MRI;
- •Inability to have an MRI;
- •Inability to undergo general anesthesia required for tunneling of extension cable and placement of the batteries;
- •Pregnancy or lack of use of effective contraception in women of childbearing age, as assessed by urine pregnancy test and self-report (participants will consent to continue effective contraceptives during the study);
- •Coagulopathy, as determined by PT, PTT, platelet count, and medical history;
- •History of recurrent infections;
- •Inability to adhere to the requirements of the study;
- •Imminent risk of suicide as determined by Study Psychiatrist's assessment and investigators' clinical judgment or past-year suicide attempt, any positive response on baseline Columbia Suicide Severity Scale or history of parental completed suicide;
- •Active criminal justice involvement (i.e., any unresolved legal problems that could jeopardize continuation or completion of the study);
- •History of head injury with loss of consciousness for more than 15 minutes, neurological illness (including primary seizure disorder);
- •Diagnosis of dementia;
- •Conditions requiring diathermy.
结局指标
主要结局
Incidence of study-emergent adverse events
时间窗: 56 weeks
Participants will be closely monitored for adverse events throughout the study including regular meetings with study staff and administration of the COMBINE SAFTEE during each programming session.
次要结局
- MRI(56 weeks)
- Behavioral Inhibition System/Behavioral Approach System (BIS/BAS)(56 weeks)
- Impulsiveness(56 weeks)
- Sensation seeking(56 weeks)
- Anhedonia(56 weeks)
- Delay Discounting(56 weeks)
- Risk taking(56 weeks)
- Local Field Potential(baseline through week 56)
- Methamphetamine craving(Comparing weeks 26-30 and weeks 52-56)
- Methamphetamine use(Measured during weeks 26-30 and weeks 52-56 (last month on stimulation and sham))
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
早期 1 期
Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid AddictionAddictionNCT01245075Jens Kuhn10
Unknown
不适用
Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule for Severe Alcohol AddictionAddictionNCT01658592Guodong Gao20
撤回
2 期
Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar DisorderBipolar DisorderNCT01372722University Hospital, Bonn
Unknown
不适用
Deep Brain Stimulation of Nucleus Accumbens for Methamphetamine AddictionTreatment Methamphetamine AddictionNCT03347474Ruijin Hospital10
已完成
不适用
Evaluating Unilateral Deep Brain Stimulation in Patients With Obsessive Compulsive DisorderObsessive-Compulsive DisorderNCT03894397KU Leuven9